α粒子放射性配体治疗后肾毒性早期检测生物标志物的临床前评估
该临床前研究在CD-1 Elite小鼠中使用[212Pb]Pb-MC1L进行剂量递增治疗,评估肾小管损伤生物标志物能否早期检测α粒子放射性配体治疗后的肾毒性。结果显示治疗后次日尿中性粒细胞明胶酶相关脂质运载蛋白(NGAL)排泄呈剂量依赖性,且与晚期肾小管间质损伤严重程度高度相关。作者认为尿NGAL分泌可能成为识别未被发现的肾小管损伤并预测长期肾毒性的潜在早期诊断工具。
要点
- 小鼠接受6.7 MBq [212Pb]Pb-MC1L后28周出现显著体重下降及基于血清肌酐、胱抑素C和组织学的慢性肾病证据。
- 治疗后次日尿NGAL排泄呈剂量依赖性,与晚期肾小管间质损伤严重程度高度相关。
- 作者认为尿NGAL可能成为识别未察觉肾小管损伤并预测长期α-RLT肾毒性的潜在早期诊断工具。
核心结论
- 作者认为尿NGAL分泌可能成为识别未被发现的肾小管损伤并预测长期α-RLT相关肾毒性的潜在早期诊断工具。
研究设计与样本
- 临床前研究:在CD-1 Elite小鼠中使用双功能环肽黑皮质素1配体(MC1L)标记的[203Pb]Pb-MC1L进行[212Pb]Pb-MC1L生物分布和吸收剂量测量。
- 小鼠接受[212Pb]Pb-MC1L剂量递增治疗,放射性活度水平旨在诱导肾损伤,并进行前瞻性肾功能与损伤生物标志物评估及晚期肾脏组织学分析以验证这些生物标志物。
主要发现
- 生物分布分析显示[212Pb]Pb-MC1L在肾脏中被重吸收,注射0.9、3.0和6.7 MBq [212Pb]Pb-MC1L的剂量沉积分别为2.8、8.9和20 Gy。
- 接受6.7 MBq的小鼠在治疗后28周出现显著体重下降,并基于血清肌酐、胱抑素C和肾脏组织学改变显示慢性肾病证据。
- 治疗后次日尿NGAL排泄呈剂量依赖性,且与晚期肾小管间质损伤严重程度和组织学发现高度相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cancer treatment with alpha-emitter-based radioligand therapies (α-RLTs) demonstrates promising tumor responses. Radiolabeled peptides are filtered through glomeruli, followed by potential reabsorption of a fraction by proximal tubules, which may cause acute kidney injury (AKI) and chronic kidney disease (CKD). Because tubular cells are considered the primary site of radiopeptides' renal reabsorption and potential injury, the current use of kidney biomarkers of glomerular functional loss limits the evaluation of possible nephrotoxicity and its early detection. This study aimed to investigate whether urinary secretion of tubular injury biomarkers could be used as an additional non-invasive sensitive diagnostic tool to identify unrecognizable tubular damage and risk of long-term α-RLT nephrotoxicity. METHODS: A bifunctional cyclic peptide, melanocortin 1 ligand (MC1L), labeled with [203Pb]Pb-MC1L, was used for [212Pb]Pb-MC1L biodistribution and absorbed dose measurements in CD-1 Elite mice. Mice were treated with [212Pb]Pb-MC1L in a dose-escalation study up to levels of radioactivity intended to induce kidney injury. The approach enabled prospective kidney functional and injury biomarker evaluation and late kidney histological analysis to validate these biomarkers. RESULTS: Biodistribution analysis identified [212Pb]Pb-MC1L reabsorption in kidneys with a dose deposition of 2.8, 8.9, and 20 Gy for 0.9, 3.0, and 6.7 MBq injected [212Pb]Pb-MC1L doses, respectively. As expected, mice receiving 6.7 MBq had significant weight loss and CKD evidence based on serum creatinine, cystatin C, and kidney histological alterations 28 weeks after treatment. A dose-dependent urinary neutrophil gelatinase-associated lipocalin (NGAL, tubular injury biomarker) urinary excretion the day after [212Pb]Pb-MC1L treatment highly correlated with the severity of late tubulointerstitial injury and histological findings. CONCLUSION: Urine NGAL secretion could be a potential early diagnostic tool to identify unrecognized tubular damage and predict long-term α-RLT-related nephrotoxicity.
引用
- Li M, Robles-Planells C, Liu D, et al. Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy. Eur J Nucl Med Mol Imaging. 2023. PMID: 38095674. doi:10.1007/s00259-023-06559-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。